Literature DB >> 23888365

Treatment challenges in axial spondylarthritis and future directions.

Joachim Sieper1.   

Abstract

Major progress has been made in recent years in the management of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). Most predictors of response have been defined for TNF-blocker therapy, and new treatment strategies are being discussed about how to best reach remission and how to maintain remission. Other biologics besides TNF-blockers have been tested in AS but have so far failed. The IL-17/IL-23 cytokines currently seem to be the most interesting targets. Short-term TNF-blocker therapy does not inhibit radiographic progression but long-term might do so. NSAIDs have been proven to inhibit such progression, even after 2 years of treatment. The effect of a combined therapy of NSAIDs with TNF-blockers on the inhibition of new bone formation in AS patients is currently unknown.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23888365     DOI： 10.1007/s11926-013-0356-9

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  45 in total

1.  A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry.

Authors:  Lydia G Schipper; Marloes Vermeer; Hillechiena H Kuper; Monique O Hoekstra; Cees J Haagsma; Alfons A Den Broeder; Piet van Riel; Jaap Fransen; Mart A F J van de Laar
Journal:  Ann Rheum Dis       Date:  2011-12-30       Impact factor: 19.103

2.  MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib.

Authors:  S J Jarrett; F Sivera; L S Cawkwell; H Marzo-Ortega; D McGonagle; E Hensor; L Coates; P J O'Connor; A Fraser; P G Conaghan; P Emery
Journal:  Ann Rheum Dis       Date:  2008-10-24       Impact factor: 19.103

3.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

4.  Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.

Authors:  Désirée van der Heijde; Robert Landewé; Xenofon Baraliakos; Harry Houben; Astrid van Tubergen; Paul Williamson; Weichun Xu; Daniel Baker; Neil Goldstein; Jürgen Braun
Journal:  Arthritis Rheum       Date:  2008-10

5.  Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Authors:  Martin Rudwaleit; Filip Van den Bosch; Martina Kron; Sonja Kary; Hartmut Kupper
Journal:  Arthritis Res Ther       Date:  2010-06-16       Impact factor: 5.156

6.  MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.

Authors:  M Rudwaleit; S Schwarzlose; E S Hilgert; J Listing; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2007-11-15       Impact factor: 19.103

7.  Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

Authors:  Xenofon Baraliakos; Hildrun Haibel; Joachim Listing; Joachim Sieper; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2013-03-16       Impact factor: 19.103

Review 8.  Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective.

Authors:  Fabien B Vincent; Eric F Morand; Kim Murphy; Fabienne Mackay; Xavier Mariette; Christian Marcelli
Journal:  Ann Rheum Dis       Date:  2012-11-24       Impact factor: 19.103

9.  The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.

Authors:  Marte Schrumpf Heiberg; Wenche Koldingsnes; Knut Mikkelsen; Erik Rødevand; Cecilie Kaufmann; Petter Mowinckel; Tore K Kvien
Journal:  Arthritis Rheum       Date:  2008-02-15

10.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103
View more
  2 in total

1.  Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.

Authors:  Karel Pavelka; Alan Kivitz; Eva Dokoupilova; Ricardo Blanco; Marco Maradiaga; Hasan Tahir; Luminita Pricop; Mats Andersson; Aimee Readie; Brian Porter
Journal:  Arthritis Res Ther       Date:  2017-12-22       Impact factor: 5.156

2.  CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.

Authors:  Ariane Hammitzsch; Cynthia Tallant; Oleg Fedorov; Alison O'Mahony; Paul E Brennan; Duncan A Hay; Fernando O Martinez; M Hussein Al-Mossawi; Jelle de Wit; Matteo Vecellio; Christopher Wells; Paul Wordsworth; Susanne Müller; Stefan Knapp; Paul Bowness
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.